Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 04, 2024 01:15 ET | Source: Novartis Pharma AG

Novartis presents new data on safety and efficacy of Zolgensma, including maintained and improved motor milestones in older and heavier children with SMA

The SMART study supplements a growing body of evidence on the use of Zolgensma in a patient population older and heavier (1.5 – 9.1 years of age) than the children treated in previous clinical studies...
February 05, 2024 16:45 ET | Source: Novartis Pharma AG

Novartis to strengthen oncology pipeline with agreement to acquire MorphoSys AG for EUR 68 per share or an aggregate of EUR 2.7bn in cash

Transaction to include pelabresib, a late-stage BET inhibitor for myelofibrosis (MF) and tulmimetostat, an early-stage investigational dual inhibitor of EZH2 and EZH1 for solid tumors or...
January 31, 2024 01:00 ET | Source: Novartis Pharma AG

Starkes Jahresergebnis: Novartis steigert den Nettoumsatz um 10%, das operative Kernergebnis um 18% (kWk¹) sowie die Margen. Weitere Innovationsdynamik mit mehreren positiven Phase-3-Ergebnissen

Ad-hoc-Mitteilung gemäss Art. 53 KR Geschäftsjahr (fortzuführende Geschäftsbereiche2)Der Nettoumsatz wuchs um +10% (kWk, +8% USD), und das operative Kernergebnis verbesserte sich um +18%...
January 31, 2024 01:00 ET | Source: Novartis Pharma AG

Novartis : forte performance en 2023, hausse de 10 % du chiffre d’affaires net et de 18 % du résultat opérationnel core (tcc¹), expansion de la marge. Innovation : nombreux résultats positifs de phase III

Annonce événementielle au sens de l’art. 53 RCExercice complet (activités poursuivies2)Hausse de +10 % (tcc, +8 % USD) du chiffre d’affaires net et de +18 % (tcc, +11 % USD) du...
January 31, 2024 01:00 ET | Source: Novartis Pharma AG

Novartis delivers strong full year performance, 10% net sales and 18% core operating income growth (cc¹), with margin expansion. Continuing innovation momentum with multiple positive Ph3 readouts

Ad hoc announcement pursuant to Art. 53 LRFull year (continuing operations2)Net sales grew +10% (cc, +8% USD) with core operating income growing +18% (cc, +11% USD)Sales growth was mainly driven by...
January 19, 2024 10:00 ET | Source: Novartis Pharma AG

Novartis Lutathera® significantly reduced risk of disease progression or death by 72% as first-line treatment for patients with advanced gastroenteropancreatic neuroendocrine tumors

In the Phase III NETTER-2 trial, Lutathera plus octreotide LAR significantly extended median PFS to 22.8 months vs. 8.5 months with high-dose octreotide LAR in patients with newly diagnosed grade 2...
January 08, 2024 01:15 ET | Source: Novartis Pharma AG

Novartis Scemblix® shows superior major molecular response (MMR) rates vs. standard‐of‐care TKIs in Phase III trial for newly diagnosed patients with chronic myeloid leukemia

MEDIA & INVESTOR RELEASE Novartis Scemblix® shows superior major molecular response (MMR) rates vs. standard-of-care TKIs in Phase III trial for newly diagnosed patients with chronic myeloid...
January 05, 2024 09:23 ET | Source: Novartis Pharma AG

Novartis expands production of Pluvicto™ with addition of its largest and most advanced radioligand therapy manufacturing facility in Indianapolis

FDA approval of the company’s second US Radioligand Therapy (RLT) manufacturing facility increases RLT production capacity to 250,000 doses in 2024 and beyondNew 70,000-square foot RLT facility is the...
December 11, 2023 01:15 ET | Source: Novartis Pharma AG

Novartis investigational iptacopan Phase III study demonstrates clinically meaningful and statistically significant proteinuria reduction in patients with C3 glomerulopathy (C3G)

Ad hoc announcement pursuant to Art. 53 LR Phase III APPEAR-C3G study met its primary endpoint, demonstrating superiority of iptacopan vs. placebo in proteinuria reduction at six-month analysis1;...
December 10, 2023 19:30 ET | Source: Novartis Pharma AG

Novartis presents new 48-week results from Phase III APPLY-PNH trial showing sustained efficacy and long-term safety of Fabhalta® (iptacopan) in adults with paroxysmal nocturnal hemoglobinuria (PNH)

APPLY-PNH extension data show that continuous Fabhalta® (iptacopan) treatment in adults with paroxysmal nocturnal hemoglobinuria (PNH) enabled sustained hemoglobin-level increases to...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right